COCP Cocrystal Pharma Inc Total Asset Value of Company

Cocrystal Pharma, Inc. (COCP) possesses significant market influence due to its innovative methods for combating viral replication. This price chart illustrates total assets at 6.58, while the company develops treatments for hepatitis and influenza relying on external funding. However, the risk of clinical trial failure and a persistent lack of operating profit create a heavy dependence on new equity issuances.

COCP (Cocrystal Pharma, Inc.) Company Total Assets history from 07/04/2022 to 10/29/2026

Analytical breakdowns and data insights for company Cocrystal (COCP)

- current price and projected stock value:

Quote Chart cocrystalpharma.com|COCP - Price Target Chart

- market capitalization data:

Market Valuation Cocrystal Pharma Corp|COCP - Enterprise Value

- issuer book value statistics:

Accounting Value of a Share Cocrystal Pharma|COCP - Book Capitalization|Market Capitalization to Book Value Ratio cocrystalpharma.com|COCP - Aggregate Company Assets

- debt burden and liquidity indicators:

All Debt to Shareholders' Equity Ratio Cocrystal Pharma, Inc.|COCP - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Cocrystal Pharma Corp|COCP - Company Aggregate Debts|Debts to Book Capitalization Cocrystal Pharma Corp|COCP - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Cocrystal Pharma|Quick Liquidity cocrystalpharma.com

- net income and valuation multiples indicators:

COCP - Net Profit

Fundamental valuation:Cocrystal Pharma, Inc.

Manufactured products of Cocrystal Pharma, Inc.

A comparative analysis of capital dynamics allows an investor to assess the business resilience of Cocrystal Pharma, Inc. (COCP), where the total value of resources is reverse-engineered through return on assets (ROA) to identify real management efficiency. The absence of in-house manufacturing capacities and the utilization of CDMO contractors optimize the balance sheet structure, which, through an analysis of all company resources, confirms a commitment to minimizing capital expenditures.

Key competitors

Total Asset Value of Company GILD (gilead.com)|Aggregate Company Assets cidara.com|Novavax Inc - Total Asset Value of Company|Company Total Assets CVAC|VALN (Valneva Vaccines) - Aggregate Asset Value|Company Total Assets VIR (Vir Biotechnology, Inc.)|Company Total Assets siga.com SIGA|EBS - Aggregate Company Assets|Aggregate Asset Value AVIR (Atea Pharma)|invivyd.com (IVVD) - Aggregate Company Assets|Cumulative Company Assets Enanta Pharmaceuticals, Inc|INO (Inovio Pharmaceuticals) - Company Total Assets|Company Total Assets hillevax.com|Cumulative Company Assets KLRS (Kalaris Therapeutics)|DYAI (dyadic.com) - Aggregate Asset Value|NanoViricides - Cumulative Company Assets|Talphera Corporation - Aggregate Company Assets|Traws Therapeutics - Company Total Assets|Company Total Asset Base Dogwood Therapeutics, Inc. DWTX|Qualigen Therapeutics, Inc. (QLGN) - Aggregate Company Assets|AlloVir - Aggregate Asset Value|Cumulative Company Assets VBIV|Company Total Assets Virios|Aggregate Company Assets Vaxart, Inc. (VXRT)